Amplia Therapeutics (Amplia Therapeutics) ROE % Adjusted to Book Value

: -14.34% (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

Amplia Therapeutics's ROE % for the quarter that ended in Sep. 2023 was -14.48%. Amplia Therapeutics's PB Ratio for the quarter that ended in Sep. 2023 was 1.01. Amplia Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2023 was -14.34%.

Amplia Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Amplia Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amplia Therapeutics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROE % Adjusted to Book Value

-50.33

-44.50

-10.11

-17.29

-26.03

Amplia Therapeutics Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
ROE % Adjusted to Book Value																-11.30	-20.95	-24.52	-31.86	-14.34

Competitive Comparison

For the Biotechnology subindustry, Amplia Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amplia Therapeutics ROE % Adjusted to Book Value Distribution

For the Biotechnology industry and Healthcare sector, Amplia Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Amplia Therapeutics's ROE % Adjusted to Book Value falls into.

Amplia Therapeutics ROE % Adjusted to Book Value Calculation

Amplia Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Mar. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-31.23%	/	1.20
	=	-26.03%

Amplia Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-14.48%	/	1.01
	=	-14.34%

Amplia Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Amplia Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Amplia Therapeutics (Amplia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amplia Therapeutics Ltd (OTCPK:INNMF) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

ATX:Australia

Address

350 Queen Street, Level 17, Melbourne, VIC, AUS, 3000

Website

https://www.ampliatx.com

Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

Amplia Therapeutics (Amplia Therapeutics) Headlines

From GuruFocus

FDA CLEARANCE OF AMPLIA'S IND FOR PANCREATIC CANCER TRIAL IN US

By PRNewswire • 01-18-2024

AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer

By PRNewswire PRNewswire • 05-29-2023

AACR OVARIAN CANCER CONFERENCE PRESENTATION

By PRNewswire • 10-09-2023